Zimbabwe has rejected a substantial US health deal valued at $367m (272 million pounds) spanning five years because of Washington's insistence on confidential information.
The decision became public after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "skewed".
An official spokesman has since stated that the US was requesting biological samples for research and profit but refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable task of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged further negotiations to secure a deal suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Background
This rejection follows a comparable situation in neighbouring Kenya, where a court suspended a related health funding agreement following concerns were filed about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking government-to-government agreements to boost openness and responsibility.
According to statements, 16 African countries have so far agreed to similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, with no corresponding guarantee of access to any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our citizens should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one deals were disrupting structures already established via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This mechanism is designed to guarantee that when a country contributes its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that respects the independence and dignity of each country."
Health Experts Response
A leading public health body stated it acknowledged the government's concerns, but recommended that talks must proceed given that much of the nation's HIV programmes depended on international support.
"Where technical issues arise, such as those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," it said.
This impasse emphasises the complex tensions between receiving vital international aid and safeguarding national sovereignty in an increasingly interconnected world.